TY - ECHAP
AU - Lehman L F
AU - Vuagnat H
AB - Hansen’s disease (HD), also known as leprosy, is a chronic disease caused by a
slowly multiplying bacillus, Mycobacterium leprae, mainly affecting skin, periph‑
eral nerves, mucosa of the upper respiratory tract, and eyes. (1) Primary nerve
impairments and disability can be prevented or minimised when disease is diag‑
nosed early and managed adequately. (1–3) The incubation period of the disease
is about five years, but symptoms can take as long as 20 years to appear. (1) The
World Health Organization (WHO) recommends MDT (multi-drug therapy) con‑
sisting of two or three drugs: dapsone and rifampicin for all plus clofazimine for
multibacillary disease.
BT - Wound and Lymphoedema Management: Focus on Resource-limited Settings
ET - 2nd Edition
LA - eng
N2 - Hansen’s disease (HD), also known as leprosy, is a chronic disease caused by a
slowly multiplying bacillus, Mycobacterium leprae, mainly affecting skin, periph‑
eral nerves, mucosa of the upper respiratory tract, and eyes. (1) Primary nerve
impairments and disability can be prevented or minimised when disease is diag‑
nosed early and managed adequately. (1–3) The incubation period of the disease
is about five years, but symptoms can take as long as 20 years to appear. (1) The
World Health Organization (WHO) recommends MDT (multi-drug therapy) con‑
sisting of two or three drugs: dapsone and rifampicin for all plus clofazimine for
multibacillary disease.
PB - World Alliance for Wound and Lymphedema Care
PY - 2020
SE - 16
SN - 978-87-971974-1-7
T2 - Wound and Lymphoedema Management: Focus on Resource-limited Settings
TI - Hansen’s Disease (Leprosy)
UR - https://wawlc.org/fileadmin/user_upload/WAWLC/WAWLC_Lymphoedema_Report_17x24_FINAL_Electr.pdf#page=118
ER -